/
CANF
$2.92+$0.17 (+6.18%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.9M
2M shares
52-week range
$2.56 – $21.80
2% from low
Exchange
XASE
ADRC
Borrow rate
141.26%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-453.08
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $2.0M | $763.0K | $853.0K | $810.0K | $743.0K | $674.0K | $408.2K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $24.2K |
| Gross profit | $3.8M | $2.0M | $763.0K | $853.0K | $810.0K | $743.0K | $674.0K | $384.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.1% |
| R&D | $6.1M | $11.0M | $12.0M | $9.8M | $7.8M | $6.0M | $5.8M | $6.7M |
| Operating income | −$5.4M | −$12.0M | −$14.1M | −$12.8M | −$10.1M | −$8.2M | −$8.1M | −$10.0M |
| EBITDA | −$6.1M | −$12.0M | −$14.1M | −$12.8M | −$10.1M | −$8.2M | −$8.1M | −$10.0M |
| Net income | −$6.6M | −$12.6M | −$14.4M | −$12.6M | −$10.2M | −$7.6M | −$7.9M | −$9.9M |
| Net margin | -172.0% | -621.3% | -1892.9% | -1476.6% | -1255.9% | -1027.5% | -1169.1% | -2426.7% |
| EPS (diluted) | -51.00 | -45.00 | -12.69 | -8.25 | -3.75 | -1.80 | -1.08 | -12.03 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21M | $-1.04 | $-1.04–$-1.04 | 1 |
| 2027 | $3M | $-0.26 | $-0.26–$-0.26 | 1 |
| 2028 | $31M | $0.09 | $0.09–$0.09 | 1 |
| 2029 | $68M | $0.33 | $0.33–$0.33 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
www.canfite.com- Employees
- 5
- IPO / List date
- Sep 10, 2012
Held by traders on TradeandTell
No one on the platform currently holds CANF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CANF as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-05 | 1-for-20reverse |
| 2023-01-09 | 1-for-10reverse |
| 2019-05-10 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CANF yet.
